Synopsis
Synopsis
0
CEP/COS
0
JDMF
0
EU WC
0
KDMF
0
VMF
0
API
0
FDF
0
FDF Dossiers
0
FDA Orange Book
0
Europe
0
Canada
0
Australia
0
South Africa
0
Listed Dossiers
DRUG PRODUCT COMPOSITIONS
0
EDQM
0
USP
0
JP
0
Others
0
US Patents
0
US Exclusivities
0
Health Canada Patents
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
US Medicaid
NA
Annual Reports
NA
Finished Drug Prices
NA
1. Anamorelin
1. 861998-00-7
2. Anamorelin Hcl
3. Anamorelin (hydrochloride)
4. Anamorelin Hydrochloride [usan]
5. Rc-1291 Hcl
6. Rc-1291 Hydrochloride
7. 55f75ljq0v
8. (3r)-1-((2r)-2-((2-amino-2-methylpropanoyl)amino)-3-(indol-3-yl)propanoyl)-3-benzyl-n,n',n'-trimethylpiperidine-3-carbohydrazide Hydrochloride
9. 3-piperidinecarboxylic Acid, 1-(2-methylalanyl-d-tryptophyl)-3-(phenylmethyl)-, Trimethylhydrazide, Monohydrochloride, (3r)-
10. Unii-55f75ljq0v
11. Ono-7643 Hydrochloride
12. Schembl4535148
13. Chembl2103794
14. Dtxsid70235443
15. Bcp15207
16. Anamorelin Hydrochloride (jan/usan)
17. Anamorelin Hydrochloride [mi]
18. Hy-14734a
19. Mfcd23098788
20. Anamorelin Hydrochloride [jan]
21. Akos030526940
22. Cs-1037
23. Anamorelin Hydrochloride [who-dd]
24. Ac-29222
25. D08856
26. Q27261306
27. 2-amino-n-((r)-1-((r)-3-benzyl-3-(1,2,2-trimethylhydrazine-1-carbonyl)piperidin-1-yl)-3-(1h-indol-3-yl)-1-oxopropan-2-yl)-2-methylpropanamide Hydrochloride
28. 2-amino-n-[(2r)-1-[(3r)-3-benzyl-3-[dimethylamino(methyl)carbamoyl]piperidin-1-yl]-3-(1h-indol-3-yl)-1-oxopropan-2-yl]-2-methylpropanamide;hydrochloride
Molecular Weight | 583.2 g/mol |
---|---|
Molecular Formula | C31H43ClN6O3 |
Hydrogen Bond Donor Count | 4 |
Hydrogen Bond Acceptor Count | 5 |
Rotatable Bond Count | 9 |
Exact Mass | 582.3085169 g/mol |
Monoisotopic Mass | 582.3085169 g/mol |
Topological Polar Surface Area | 115 Ų |
Heavy Atom Count | 41 |
Formal Charge | 0 |
Complexity | 904 |
Isotope Atom Count | 0 |
Defined Atom Stereocenter Count | 2 |
Undefined Atom Stereocenter Count | 0 |
Defined Bond Stereocenter Count | 0 |
Undefined Bond Stereocenter Count | 0 |
Covalently Bonded Unit Count | 2 |
Treatment of anorexia, cachexia or unintended weight loss in adult patients with non-small cell lung cancer (NSCLC)
Treatment of cancer related cachexia
V03
ABOUT THIS PAGE
LOOKING FOR A SUPPLIER?